Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $15.00.

AMRX has been the topic of a number of analyst reports. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Truist Financial lifted their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. UBS Group began coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st.

Amneal Pharmaceuticals Trading Up 1.3%

Shares of AMRX opened at $12.73 on Wednesday. Amneal Pharmaceuticals has a twelve month low of $7.02 and a twelve month high of $15.42. The stock’s 50 day moving average is $12.95 and its two-hundred day moving average is $12.61. The firm has a market capitalization of $4.01 billion, a PE ratio of 33.50 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a negative return on equity of 276.67% and a net margin of 4.53%.The company had revenue of $723.00 million for the quarter, compared to analyst estimates of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. On average, sell-side analysts predict that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors have recently modified their holdings of AMRX. Assenagon Asset Management S.A. boosted its stake in shares of Amneal Pharmaceuticals by 75.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after acquiring an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $13,833,000. Morgan Stanley boosted its stake in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after acquiring an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Amneal Pharmaceuticals by 1,440.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after acquiring an additional 1,062,045 shares in the last quarter. Finally, Penn Capital Management Company LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $12,655,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.